Cytokinetics Inc. Stock
Cytokinetics Inc. Stock
Cytokinetics Inc. shows a slight decrease today, losing -€0.500 (-0.870%) compared to yesterday.
The stock is an absolute favorite of our community with 34 Buy predictions and no Sell predictions.
As a result the target price of 74 € shows a positive potential of 30.97% compared to the current price of 56.5 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -0.870% | -4.237% | 8.654% | 18.697% | 24.449% | 55.220% | 279.195% |
| Ardelyx Inc. | -0.470% | 1.501% | -0.696% | -1.154% | 3.525% | 187.536% | -1.306% |
| Krystal Biotech | 5.350% | 6.399% | 15.665% | 18.562% | 32.194% | 164.737% | - |
| Evolus Inc | 0.890% | -5.042% | -1.739% | -52.521% | -46.190% | -16.296% | 86.346% |
Comments
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Royal Bank Of Canada from $82.00 to $87.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at B. Riley. They now have a $90.00 price target on the stock, up previously from $80.00.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
News
CYTK Earnings Jump 3,065%
Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic
